Offering
Sermorelin Therapy listed
Price access
Sign-in required
Account
Free account creation advertised
Eligibility
Licensed-provider review described
Formulation
Current details not publicly established

What can be verified without an account

Valhalla Vitality has a current Sermorelin Therapy listing within its peptide and other-therapy catalog. The public page asks visitors to create an account or sign in to see pricing, dosing and full details. It describes account creation as free and links that process to an eligibility check by a licensed provider. Those are the facts available for a public comparison on October 11, 2026.

The listing does not provide enough visible detail to publish a current vial price, recurring total or specific supplied formulation. We leave those fields unquoted rather than filling gaps with estimates.

Why an older product address is not a current quote

An older address containing “15-mg” now redirects to the general Sermorelin Therapy page. Search engines may retain descriptions or prices associated with that older page. A historical URL and a cached snippet do not establish what a new patient can actually buy today.

This matters particularly when an older offering included several strengths or combination products. A price range spanning different selections cannot be reduced to a single monthly sermorelin price without knowing the current formulation, quantity, administration route and period covered. The present account screen must supply those details.

What to request after signing in

Start with the exact product name and ingredients, then ask for the medication amount, days of supply and whether the selected price represents one shipment or a subscription. Obtain the consultation, laboratory and delivery charges separately. If several formulations appear, keep each in a separate comparison rather than averaging prices across them.

Before supplying payment information, locate the first charge, subsequent charge and cancellation deadline. Free account creation does not mean the medical consultation, testing or treatment is free. It simply means the account-entry step is described that way.

Access and clinical review are separate questions

A gated catalog is neither proof of poor care nor proof of personalized care. It changes how much a reader can compare before sharing information. Consider whether you are comfortable creating an account and providing the requested information to obtain a complete quote, then evaluate the actual prescription process on its own terms.

Ask how to contact the clinician, which pharmacy would dispense the medication and how a pharmacy question is escalated. The published support hours provide an administrative contact window, not evidence of a particular medical response time or emergency service.

How this provider belongs in the comparison

Valhalla is included because its current official catalog names sermorelin, not because we have established a competitive price or tested its service. Its main unresolved issue for this guide is public cost transparency. A reader with an individualized written quote can compare it against the more openly priced plans, provided the ingredients and supply period match.

The page discloses that compounded drugs have not been evaluated or approved by the FDA. Keep that distinction even if an account later shows pharmacy credentials or product-testing documents. Those documents may answer quality questions, but they do not convert the compounded prescription into an FDA-approved anti-aging treatment.

Useful distinctions

  • Current official sermorelin listing
  • Free account-entry step described
  • Licensed-provider eligibility review stated

Limitations to weigh

  • Price and full terms are account-gated
  • Current formulation and route need confirmation
  • Older URL prices are not used

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. Valhalla Vitality: Sermorelin Therapy Provider
  2. FDA: Understanding the Risks of Compounded Drugs Regulatory